Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin‐1‐Mediated PI3K / AKT Signaling Pathway in Cisplatin‐Resistant Cervical Cancer Cells
The FASEB Journal · 2026
DOI: 10.1096/fj.202504556rr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2026. Verfasst von Yujia Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Provincial Clinical Research Center for Gynecological Diseases, Department of Obstetrics and Gynecology, The Second Affiliated Hospital of W…. Hauptthemen laut MEDLINE: Cisplatin, Caveolin 1, Simvastatin, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Natural Science Foundation of Zhejiang Province, Zhejiang Key Laboratory of Traditional Chinese Medicine for Diagnosis and Treatment of Gynecological Cancers.
Abstract (Originalsprache)
Cervical cancer treatment is often hindered by the emergence of cisplatin (DDP) resistance. Increasing evidence has indicated that statins possess anti‐tumor and chemosensitization potential beyond their lipid‐lowering effects. Statin utilization is found to be significantly linked to decreased cervical cancer incidence and mortality. However, whether statins affect chemosensitivity to cisplatin in cisplatin‐resistant cervical cancer remains to be clarified. In cervical cancer cisplatin‐resistant cell lines (SiHa‐DDP and C33a‐DDP) constructed from their parental cells, the effects of seven statins (simvastatin, fluvastatin, pitavastatin, lovastatin, atorvastatin, rosuvastatin, and pravastatin) on cell viability in cisplatin‐resistant cells and corresponding parental cells were assessed using the CCK‐8 assay. Compared with parental counterparts, the IC 50 values of seven statin drugs were markedly elevated in cells exhibiting cisplatin resistance. Simvastatin significantly enhanced the efficacy of cisplatin in cisplatin‐resistant cervical cancer cells, demonstrating a synergistic anti‐cancer effect (CI < 1). Combined therapy using simvastatin and cisplatin inhibited cell viability and migration while promoting cell apoptosis. Mechanistically, simvastatin downregulated protein expressions of caveolin‐1 (CAV1), PI3K, and p‐AKT. CAV1 knockdown in SiHa‐DDP and C33a‐DDP cells markedly increased cisplatin sensitivity, confirming its critical role in chemoresistance. Rescue experiments showed that CAV1 overexpression partially counteracted the inhibitory effects of simvastatin. In vivo, compared with monotherapies, simvastatin combined with cisplatin treatment markedly suppressed tumor growth, reduced CAV1 protein expression, decreased the percentage of Ki67‐positive cells and promoted apoptosis. In all, simvastatin enhanced cisplatin sensitivity by suppressing the CAV1‐mediated PI3K/AKT pathway involvement in the development of cisplatin resistance in cervical cancer cells. These findings reveal a novel mechanism in cervical cancer cells resistant to cisplatin by which simvastatin may serve as a potential adjuvant to improve the therapeutic efficacy of cisplatin‐based chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhejiang Provincial Clinical Research Center for Gynecological Diseases, Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China.
- Alberta Institute, Wenzhou Medical University, Wenzhou, People's Republic of China.
ORCID-Profile: Xueqiong Zhu
Förderung
- the Natural Science Foundation of Zhejiang Province
- Zhejiang Key Laboratory of Traditional Chinese Medicine for Diagnosis and Treatment of Gynecological Cancers
Zitieren
APA
Zhou, Y., Liu, H., Pan, S., Ruan, L., Ruan, J., Chen, J., Ji, H., & Zhu, X. (2026). Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin‐1‐Mediated PI3K / AKT Signaling Pathway in Cisplatin‐Resistant Cervical Cancer Cells. The FASEB Journal. https://doi.org/10.1096/fj.202504556rr
Vancouver
Zhou Y, Liu H, Pan S, Ruan L, Ruan J, Chen J, et al. Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin‐1‐Mediated PI3K / AKT Signaling Pathway in Cisplatin‐Resistant Cervical Cancer Cells. The FASEB Journal. 2026. doi:10.1096/fj.202504556rr
BibTeX
@article{Zhou2026,
author = {Zhou, Yujia and Liu, Hejing and Pan, Shuangjia and Ruan, Luyi and Ruan, Jiayi and Chen, Jiaru and Ji, Huihui and Zhu, Xueqiong},
title = {Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin‐1‐Mediated PI3K / AKT Signaling Pathway in Cisplatin‐Resistant Cervical Cancer Cells},
journal = {The FASEB Journal},
year = {2026},
doi = {10.1096/fj.202504556rr}
}
EUVIMED